GREENROSE ACQUISITION CORP, 2019-12-27 Public Filing Price Range: Pending Shares to be Issued: 15.00M Offering Price: 10.00 Post IPO Outstanding: Pending Expected Listing Date: 2020-02-12 About GRACU: Our initial business combination and value creation strategy will be to identify, acquire and, after our initial business combination, assist in the growth of a business in the cannabis industry. HUIZE HOLDING LTD, 2019-09-04 Public Filing Price Range: 9.40~11.40 Shares to be Issued: Pending Offering Price: Pending Post IPO Outstanding: Pending Expected Listing Date: 2020-02-12 About HUIZ: Smart Choice Holding Ltd is an investment company, headquartered in China. It was founded in 2014. Use of Proceeds We estimate that we will receive net proceeds from this offering of approximately US$ , or approximately US$ if the underwriters exercise their over-allotment option in full, after deducting underwriting discounts and commissions and the estimated offering expenses payable by us. NEWBORN ACQUISITION CORP 2020-01-03 Public Filing Price Range: Pending Shares to be Issued: 5000.00K Offering Price: 10.00 Post IPO Outstanding: Pending Expected Listing Date: 2020-02-12 About NBACU: We will seek to capitalize on the experience and networks of our management team, Mr. Wenhui Xiong, Mr. Jianjun Nie, Mr. H. David Sherman, Mr. Jianjun Lu and Ms. Li Wan. Our team consists of seasoned and experienced professionals who have experience in equity investments, finance, business operations and management, as well as deal negotiation. REVOLUTION MEDICINES, INC. 2020-01-17 Public Filing Price Range: 14.00~16.00 Shares to be Issued: 10.00M Offering Price: Pending Post IPO Outstanding: Pending Expected Listing Date: 2020-02-13 About RVMD: Revolution Medicines, Inc. is a United States-based clinical-stage precision oncology company. The Company is focused on developing medicines for cancer patients. Its pipeline includes RMC-4630, SOS1, RMC-5552 and Mutant-selective renin angiotensin system (RAS) inhibitors. RMC-4630 is a potent and selective inhibitor of SHP2. SOS1 is being developed for targeting RAS-driven tumors. RMC-5552 is a potent and selective inhibitor of mTORC1. F5 FINISHES, INC 2019-11-07 Public Filing Price Range: 7.00~8.00 Shares to be Issued: 5000.00K Offering Price: 5.00 Post IPO Outstanding: 9165.97K Expected Listing Date: 2020-02-14 About FLRZ: F5 Finishes Inc, located in Livermore, California, provides flooring contracting services. The Company also includes sales, installation and maintenance services for existing and new commercial buildings. The Company was founded in 2007.